The company also secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat hypertension.
According to IMS Health, Valsartan Tablets USP 40mg, 80mg, 160mg, and 320mg, had US sales of about $2bn for the 12 months ending 30 September 2014.
Around 284 of Mylan ANDAs that represent $109.2bn in annual sales are still awaiting clearance from the FDA, with 44 of them being potential first-to-file opportunities, signifying $29.3bn in annual brand sales, for the year ending 30 June 2014.
The company provides a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications.
Additionally, the company offers a wide range of antiretroviral therapies, upon which about 40% of HIV/AIDS patients in developing countries depend.
The company also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 140 countries and territories.